Galapagos (NASDAQ:GLPG) Receives “Neutral” Rating from UBS Group


Share on StockTwits

Galapagos (NASDAQ:GLPG)‘s stock had its “neutral” rating restated by research analysts at UBS Group in a research report issued on Monday, The Fly reports.

Several other brokerages have also recently issued reports on GLPG. Bank of America raised Galapagos from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $93.00 to $94.00 in a report on Tuesday, February 23rd. Maxim Group cut Galapagos from a “buy” rating to a “hold” rating in a report on Wednesday, February 10th. Smith Barney Citigroup reissued a “buy” rating on shares of Galapagos in a report on Thursday, December 17th. Bryan, Garnier & Co cut Galapagos from a “buy” rating to a “sell” rating in a report on Thursday, December 17th. Finally, Barclays reaffirmed an “equal weight” rating on shares of Galapagos in a report on Tuesday, March 2nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $150.08.

Shares of GLPG stock opened at $78.30 on Monday. The stock has a market cap of $5.13 billion, a PE ratio of -11.86 and a beta of 0.76. The business has a 50-day simple moving average of $80.85 and a 200-day simple moving average of $106.48. Galapagos has a 52-week low of $74.51 and a 52-week high of $233.14.

A number of large investors have recently bought and sold shares of GLPG. OLD Mission Capital LLC increased its stake in Galapagos by 290.1% during the 3rd quarter. OLD Mission Capital LLC now owns 113,719 shares of the biotechnology company’s stock worth $16,138,000 after buying an additional 84,569 shares in the last quarter. Morgan Stanley increased its stake in Galapagos by 153.8% during the 4th quarter. Morgan Stanley now owns 127,657 shares of the biotechnology company’s stock worth $12,636,000 after buying an additional 77,366 shares in the last quarter. Voloridge Investment Management LLC increased its stake in Galapagos by 647.7% during the 4th quarter. Voloridge Investment Management LLC now owns 84,802 shares of the biotechnology company’s stock worth $8,394,000 after buying an additional 73,460 shares in the last quarter. Norges Bank purchased a new stake in Galapagos during the 4th quarter worth approximately $6,929,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Galapagos during the 3rd quarter worth approximately $1,548,000. Institutional investors own 11.17% of the company’s stock.

About Galapagos

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, and psoriatic arthritis.

See Also: What is the CAC 40 Index?

The Fly

Analyst Recommendations for Galapagos (NASDAQ:GLPG)

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.